Ongoing progress in BRAF-mutated non-small cell lung cancer

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Activating BRAF mutations occur in 1.5%–4.5% of non-small cell lung cancer (NSCLC) patients.
• These mutations impact key cellular processes including proliferation and survival via the MAPK/ERK pathway.
• Current first-line treatment involves dabrafenib and trametinib for BRAF V600-mutated NSCLC.

Purpose of the Study:

• To review the efficacy of current treatments for BRAF-mutated NSCLC.
• To highlight limitations of existing therapies, especially for non-V600 BRAF mutations.
• To discuss emerging therapeutic strategies and research directions.

Main Methods:

• Review of pivotal phase 2 study data for dabrafenib and trametinib combination therapy.
• Analysis of the impact of BRAF mutations on NSCLC pathogenesis.
• Survey of ongoing clinical trials for novel BRAF inhibitors and combination therapies.

Main Results:

• The combination of dabrafenib and trametinib showed an objective response rate of 64% and median progression-free survival of 10.2 months.
• Treatment outcomes remain suboptimal compared to other targeted therapies for NSCLC.
• First-generation BRAF inhibitors lack efficacy in class II and III BRAF mutations.

Conclusions:

• Improved treatment strategies are needed for BRAF-mutated NSCLC, particularly for non-V600 mutations.
• Novel RAF inhibitors and combination therapies, including immune checkpoint inhibitors, are under investigation.
• Expert referral, basket trials, and advanced biopsies are crucial for advancing care.